These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 11376626

  • 1. Dystrophin-deficient myocardium is vulnerable to pressure overload in vivo.
    Kamogawa Y, Biro S, Maeda M, Setoguchi M, Hirakawa T, Yoshida H, Tei C.
    Cardiovasc Res; 2001 Jun; 50(3):509-15. PubMed ID: 11376626
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.
    Spurney CF, Guerron AD, Yu Q, Sali A, van der Meulen JH, Hoffman EP, Nagaraju K.
    BMC Cardiovasc Disord; 2011 May 16; 11():20. PubMed ID: 21575230
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Early right ventricular fibrosis and reduction in biventricular cardiac reserve in the dystrophin-deficient mdx heart.
    Meyers TA, Townsend D.
    Am J Physiol Heart Circ Physiol; 2015 Feb 15; 308(4):H303-15. PubMed ID: 25485898
    [Abstract] [Full Text] [Related]

  • 6. Cardiac dysfunction and pathology in the dystrophin and utrophin-deficient mouse during development of dilated cardiomyopathy.
    Chun JL, O'Brien R, Berry SE.
    Neuromuscul Disord; 2012 Apr 15; 22(4):368-79. PubMed ID: 22266080
    [Abstract] [Full Text] [Related]

  • 7. Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging.
    Verhaart IE, van Duijn RJ, den Adel B, Roest AA, Verschuuren JJ, Aartsma-Rus A, van der Weerd L.
    Neuromuscul Disord; 2012 May 15; 22(5):418-26. PubMed ID: 22209498
    [Abstract] [Full Text] [Related]

  • 8. Cyclosporine reduces left ventricular mass with chronic aortic banding in mice, which could be due to apoptosis and fibrosis.
    Yang G, Meguro T, Hong C, Asai K, Takagi G, Karoor VL, Sadoshima J, Vatner DE, Bishop SP, Vatner SF.
    J Mol Cell Cardiol; 2001 Aug 15; 33(8):1505-14. PubMed ID: 11448138
    [Abstract] [Full Text] [Related]

  • 9. Defective T-lymphocyte migration to muscles in dystrophin-deficient mice.
    Cascabulho CM, Bani Corrêa C, Cotta-de-Almeida V, Henriques-Pons A.
    Am J Pathol; 2012 Aug 15; 181(2):593-604. PubMed ID: 22733008
    [Abstract] [Full Text] [Related]

  • 10. Voluntary exercise induces structural remodeling in the hearts of dystrophin-deficient mice.
    Costas JM, Nye DJ, Henley JB, Plochocki JH.
    Muscle Nerve; 2010 Dec 15; 42(6):881-5. PubMed ID: 21104863
    [Abstract] [Full Text] [Related]

  • 11. Dystrophin upregulation in pressure-overloaded cardiac hypertrophy in rats.
    Maeda M, Biro S, Kamogawa Y, Hirakawa T, Setoguchi M, Tei C.
    Cell Motil Cytoskeleton; 2003 May 15; 55(1):26-35. PubMed ID: 12673596
    [Abstract] [Full Text] [Related]

  • 12. Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch.
    Dogra C, Changotra H, Wergedal JE, Kumar A.
    J Cell Physiol; 2006 Sep 15; 208(3):575-85. PubMed ID: 16741926
    [Abstract] [Full Text] [Related]

  • 13. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
    Milad N, White Z, Tehrani AY, Sellers S, Rossi FMV, Bernatchez P.
    Skelet Muscle; 2017 Sep 12; 7(1):19. PubMed ID: 28899419
    [Abstract] [Full Text] [Related]

  • 14. Cardiomyopathy in dystrophin-deficient hypertrophic feline muscular dystrophy.
    Gaschen L, Lang J, Lin S, Adé-Damilano M, Busato A, Lombard CW, Gaschen FP.
    J Vet Intern Med; 1999 Sep 12; 13(4):346-56. PubMed ID: 10449227
    [Abstract] [Full Text] [Related]

  • 15. Cardiac-Specific Expression of ΔH2-R15 Mini-Dystrophin Normalized All Electrocardiogram Abnormalities and the End-Diastolic Volume in a 23-Month-Old Mouse Model of Duchenne Dilated Cardiomyopathy.
    Wasala NB, Shin JH, Lai Y, Yue Y, Montanaro F, Duan D.
    Hum Gene Ther; 2018 Jul 12; 29(7):737-748. PubMed ID: 29433343
    [Abstract] [Full Text] [Related]

  • 16. Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10.
    Nitahara-Kasahara Y, Hayashita-Kinoh H, Chiyo T, Nishiyama A, Okada H, Takeda S, Okada T.
    Hum Mol Genet; 2014 Aug 01; 23(15):3990-4000. PubMed ID: 24659498
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Muscle-bone interactions in dystrophin-deficient and myostatin-deficient mice.
    Montgomery E, Pennington C, Isales CM, Hamrick MW.
    Anat Rec A Discov Mol Cell Evol Biol; 2005 Sep 01; 286(1):814-22. PubMed ID: 16078270
    [Abstract] [Full Text] [Related]

  • 19. Dystrophin deficient mdx muscle is not prone to MH susceptibility: an in vitro study.
    Mader N, Gilly H, Bittner RE.
    Br J Anaesth; 1997 Jul 01; 79(1):125-7. PubMed ID: 9301401
    [Abstract] [Full Text] [Related]

  • 20. Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy.
    Bauer R, Straub V, Blain A, Bushby K, MacGowan GA.
    Eur J Heart Fail; 2009 May 01; 11(5):463-71. PubMed ID: 19233868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.